Navigation Links
Covance to Present at Morgan Stanley Global Healthcare Conference
Date:9/12/2011

PRINCETON, N.J.,, Sept. 12, 2011 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today announced that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2011 at 9:45 a.m. ET.  Investors may access a live webcast of the presentation at www.covance.com.  In order to register and download any necessary software, please log on 10 minutes early.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.9 billion, global operations in more than 30 countries, and more than 10,500 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release (and in the webcast announced in this press release), which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue, earnings growth, and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories, fluctuations in currency exchange rates, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Covance Reports Second Quarter Revenue of $518 Million, GAAP EPS of $0.61, and Pro Forma EPS of $0.66
2. Covance to Present at Bairds 2011 Growth Stock Conference
3. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2011 Financial Results Conference Call
4. Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference
5. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
6. Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56
7. Covance Reports Third Quarter Financial Results and Takes Actions to Strengthen Future Performance
8. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
9. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
10. Covance Board Authorizes $250 Million Stock Buyback
11. Covance to Present at Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... 2016 According to a ... Market by Type (Stability, Raw Materials, Method Validation, ... (Pharmaceutical Companies, Medical Device Companies) - Global Forecast ... healthy growth during the last decade and is ... between 2016 and 2021 to reach USD 4.13 ...
(Date:5/30/2016)... Eye expert s ... seek an eye examination before leaving ...   Moorfields Eye Hospital Dubai, the first overseas branch ... , has identified premature babies as a special concern in the ... vulnerability to retinopathy of prematurity (ROP). ROP is a potentially blinding ...
(Date:5/27/2016)... TEL-AVIV, Israel , May 27, 2016 /PRNewswire/ ... KTOV), an innovative biopharmaceutical company focused on late-stage ... by Dexcel Pharma of pivotal batches ... Food and Drug Administration (FDA). This follows Kitov,s ... pivotal Phase III trial successfully met its primary ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... 2016 , ... TeaZa® Energy, LLC announces the launch of a ... Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be available to customers exclusively ... The new flavor is best described as a juicy, taste bud takeover. A ...
(Date:5/31/2016)... Aviv (PRWEB) , ... May 31, 2016 , ... ... the May 4, 2016 Cool Vendors in Security Infrastructure Protection report by Gartner1 ... and publishes a series of research reports evaluating these innovative vendors and their ...
(Date:5/31/2016)... ... May 31, 2016 , ... Advertising ... firm and statement solutions provider, for the tenth consecutive year as a Top ... of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing Agency” ...
(Date:5/31/2016)... ... 31, 2016 , ... CURE Media Group , the ... added Cancer and Careers to its Advocacy Spotlight Partnership ... successful careers while fighting cancer. , As partners, both organizations will supply timely ...
(Date:5/30/2016)... Miami, FL (PRWEB) , ... May 30, 2016 , ... ... will means for their children and their efforts to keep their households lice free. ... schools across Hawaii are enacting new policies that keep kids in the classroom despite ...
Breaking Medicine News(10 mins):